TLRY
Tilray Brands, Inc.
Overview
Tilray Brands, Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $571.5M market cap.
Most recent reported earnings: Q2 FY2026 (Jul 27, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2025-10-099 Q&A exchanges
- Q4 FY2025Earnings2025-07-2814 Q&A exchanges
- Q3 FY2025Earnings2025-04-0820 Q&A exchanges
- Q2 FY2025Earnings2025-01-0923 Q&A exchanges
- Q1 FY2025Earnings2024-10-1024 Q&A exchanges
- Q4 FY2024Earnings2024-07-2920 Q&A exchanges
- Q3 FY2024Earnings2024-04-0918 Q&A exchanges
- Q2 FY2024Earnings2024-01-0920 Q&A exchanges
- Q1 FY2024Earnings2023-10-0420 Q&A exchanges
- Q4 FY2023Earnings2023-07-2611 Q&A exchanges
- Q3 FY2023Earnings2023-04-1017 Q&A exchanges
- Q2 FY2023Earnings2023-01-0917 Q&A exchanges
- Q1 FY2023Earnings2022-10-0719 Q&A exchanges
- Q4 FY2022Earnings2022-07-2831 Q&A exchanges
- Q3 FY2022Earnings2022-04-0617 Q&A exchanges
- Q2 FY2022Earnings2022-01-1013 Q&A exchanges
- Q1 FY2022Earnings2021-10-0725 Q&A exchanges
- Q4 FY2021Earnings2021-07-2811 Q&A exchanges
- Q3 FY2021Earnings2021-04-1216 Q&A exchanges
- Q2 FY2021Earnings2021-01-1418 Q&A exchanges
- Q1 FY2021Earnings2020-10-1521 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-27EPS— vs ——Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-27 | — | — | — | — | — | — | EODHD |
Source: EODHD. TLRY reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks TLRY's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.41 | $1.21 | +16.3% | +2.1% | +0.4% |
| Q4 FY2026 | $1.45 | $1.27 | +14.4% | -3.7% | -4.4% |
| Q3 FY2026 | $1.44 | $1.21 | +18.8% | +1.9% | +0.5% |
| Q2 FY2026 | $1.69 | $1.40 | +20.9% | +5.4% | +6.7% |
| Q1 FY2025 | $1.46 | $1.28 | +14.4% | 0.0% | +2.3% |
| Q4 FY2025 | $1.58 | $1.38 | +14.8% | -0.3% | -3.0% |
| Q3 FY2025 | $1.52 | $1.29 | +17.7% | +0.6% | +2.5% |
| Q2 FY2025 | $1.55 | $1.30 | +19.5% | +1.9% | +1.2% |
| Q1 FY2024 | $1.48 | $1.32 | +12.0% | +2.8% | +4.7% |
| Q4 FY2024 | $1.50 | $1.23 | +21.7% | +5.4% | +7.4% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Irwin D SimonCEO1 yr 11 mo20 callsCurrentSample
CEO since 2024 • 3/8 beats (38%) • last guidance raise Q1 FY2026
- Carl A MertonCFO1 yr 11 mo21 callsCurrentSample
CFO since 2024 • 3/8 beats (38%) • last guidance cut Q2 FY2026
- Denise M FaltischekChief Strategy Officer1 yr 11 mo13 callsCurrentSample
OTHER_C_SUITE since 2024 • 5/8 beats (63%) • guidance suspended Q3 FY2026
- Mitchell GendelGlobal General Counsel1 yr 11 mono recorded callsCurrentSample
OTHER since 2024 • 3/8 beats (38%) • last call held guidance Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TLRY.
$ curl https://api.spokenalpha.com/v1/companies/TLRYFAQ
Frequently asked about TLRY
Where can I find Tilray Brands, Inc.'s (TLRY) earnings call transcripts?
Spoken Alpha indexes TLRY's earnings call transcripts at https://spokenalpha.com/companies/TLRY. Each call links to attributed speakers and parsed analyst Q&A. Tilray Brands, Inc.'s own investor relations page is at https://ir.tilray.com/.
When was Tilray Brands, Inc.'s most recent earnings call?
Tilray Brands, Inc. (TLRY) held its most recent earnings call on 2025-10-09, covering fiscal Q1 2026.
What sector is TLRY in?
Tilray Brands, Inc. (TLRY) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).